Improving Cell Separation for Better Therapies and Greater Access

Published on Oct 28, 2025 Share Category: BACS^TM Microbubble Technology and Workflow

Akadeum CEO Brandon McNaughton returns to Cell & Gene’s Meeting on the Mesa to present significant regulatory accomplishments, clinical milestones, and recent data from industry collaborators demonstrating how better cell separation is the key to better therapies.

Presentation Highlights:

• Akadeum’s microbubble-based cell separation technology is the first and only separation technology that works entirely “in bag” for untouched, negative selection without the need for magnetics and is compatible with industry-leading systems.
• Robust GMP-quality reagents and closed systems for clinical trial readiness have been developed with regulatory filings underway.
• The first in-animal use of microbubble-separated, engineered T cells treating cancer in canines was successful with no adverse events.
• Integrating microbubble technology into your current workflow eliminates time-consuming steps and costly instruments. This approach leads to faster, more cost-efficient workflows that support clinical scalability.
• We now have data to support why better separation with Akadeum microbubbles leads to better therapies.
• Akadeum is actively collaborating with industry and academic partners and exploring strategic relationships to accelerate adoption and patient access to cell therapies.